말초혈관 중재시술 시장 예측 - 제품, 시술, 용도, 최종사용자, 지역별 분석(-2034년)

According to Stratistics MRC, the Global Peripheral Interventions Market is accounted for $11.9 billion in 2026 and is expected to reach $25.9 billion by 2034 growing at a CAGR of 10.2% during the forecast period. The term "peripheral interventions" describes medical procedures used to treat diseases affecting the arteries and veins that are not part of the heart or brain, or the peripheral vascular system. Medical professionals utilize various minimally invasive techniques during peripheral interventions, such as angioplasty, stent placement, atherectomy, and thrombectomy. Therefore, these procedures often provide effective alternatives to traditional open surgeries, offering quicker recovery times and reduced risks.

According to the American Heart Association, a patient in Canada spends around USD 4,600 per year on treatment and diagnosis of peripheral atrial disease.

Market Dynamics:

Driver:

Growing healthcare expenditure

The availability of cutting-edge tools enhances the precision and efficacy of these procedures, attracting healthcare professionals and fostering patient confidence in these advanced treatment options. Increasing financial investments in healthcare witnessed globally and particularly in developed economies, plays a crucial role in advancing medical technologies and treatment modalities. In addition, this financial support facilitates research and development, leading to continuous innovation in peripheral interventions, which is driving this market size.

Restraint:

High cost

Medical equipment and devices used in peripheral interventions can have high costs because of their expensive manufacturing, research and development in compliance with regulations. Using cutting-edge imaging techniques like intravascular ultrasound and angiography also contributes to the high price. Furthermore, this market size is being hampered by the cost of the knowledge and training needed to carry out peripheral interventions.

Opportunity:

Favorable reimbursement policies

Reimbursement structures that adequately cover the costs associated with peripheral interventions incentivize healthcare providers to offer these advanced procedures, ensuring accessibility for patients. Industry stakeholders, including manufacturers and developers of peripheral intervention technologies, also benefit from favorable reimbursement policies. Furthermore, when reimbursement aligns with the value of these interventions, it encourages healthcare facilities to invest in state-of-the-art technologies and skilled personnel, ultimately promoting the adoption of peripheral interventions and significantly propelling market growth.

Threat:

Lack of awareness and education

Physicians and healthcare providers may not be fully aware of the latest advancements, which results in a lack of awareness and underutilization of peripheral interventions as a treatment option. Limited patient education and awareness campaigns contribute to the under-recognition of symptoms, delayed diagnosis, and subsequent treatment. In addition, this lack of knowledge may lead patients to opt for traditional treatment methods or remain untreated altogether, making it complex and hampering market growth.

Covid-19 Impact

The COVID-19 pandemic has had a notable negative impact on the peripheral intervention market. The restrictions imposed to curb the spread of the virus, such as lockdowns and limitations on elective procedures, led to a significant decline in the number of non-urgent peripheral interventions. Fear of contracting the virus in hospital settings caused patients to postpone or cancel procedures, which reduced the demand for peripheral intervention services and devices. Moreover, disruptions in the global supply chain and manufacturing processes hampered market expansion.

The atherectomy devices segment is expected to be the largest during the forecast period

The atherectomy devices segment is estimated to hold the largest share due to the fact that it involves the removal of atherosclerotic plaque from blood vessels, facilitates improved blood flow, and reduces the risk of complications such as ischemia and limb-threatening conditions. It utilizes various techniques, including rotational, orbital, laser, and directional atherectomy. Additionally, their effectiveness in treating complex arterial lesions while offering advantages such as reduced trauma to the vessel walls and enhanced outcomes compared to traditional methods driving this segment's growth.

The venous thromboembolism segment is expected to have the highest CAGR during the forecast period

The venous thromboembolism segment is anticipated to have lucrative growth during the forecast period due to its ability to address medical procedures and interventions aimed at managing conditions involving blood clots within the veins. These interventions are crucial for preventing the progression of thrombotic events, reducing the risk of complications, and improving overall patient outcomes. Furthermore, mechanical thrombectomy devices may be employed to physically remove the clot, enhancing the efficacy of clot removal while minimizing invasiveness, which is boosting segment expansion.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to a robust landscape characterized by technological advancements, high healthcare expenditure, and a growing prevalence of peripheral vascular diseases. Collaborations between healthcare providers, industry stakeholders, and research institutions ensure a continuous influx of novel technologies and treatment modalities. Furthermore, favorable reimbursement policies and a proactive regulatory environment contribute to the rapid adoption of advanced peripheral intervention procedures, which are driving this region's growth.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period due to a rising prevalence of peripheral vascular diseases. Countries like China, Japan, India, and Australia are witnessing a surge in demand for advanced interventional procedures due to factors such as aging populations, lifestyle changes, and heightened awareness of minimally invasive treatment options. Additionally, peripheral interventions, including angioplasty, stenting, atherectomy, and thrombectomy, are gaining traction as viable alternatives to traditional surgical approaches, which are boosting this region's expansion.

Key players in the market

Some of the key players in the Peripheral Interventions Market include Boston Scientific Corporation, Abbott Laboratories, W. L. Gore & Associates Inc, AngioDynamics Inc., Medtronic, Teleflex Incorporated, Cardinal Health Inc, Terumo Corporation, Biotronik SE & Co. KG, C.R. Bard Inc., Cook Medical, Terumo Interventional Systems Inc, Becton Dickinson and Company, B. Braun Melsungen AG and St. Jude Medical.

Key Developments:

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

In November 2023, Terumo announced the launch of Insulin Syringe, Sterile delivery device for patients requiring regular insulin injections, thereby raising the bar for patient comfort and therapy compliance.

In June 2023, the American Diabetes Association(R) (ADA) and Abbott announced a collaboration aimed at better understanding how diabetes technology like continuous glucose monitoring (CGM) systems can help people living with diabetes make informed decisions about their food and activity.

In June 2023, Terumo Aortic announced the launch of the company's global Post-Approval Study (PAS) known as EXTEND for Thoraflex Hybrid, the only Frozen Elephant Trunk (FET) device approved by the US Food and Drug Administration (FDA) for the treatment of patients with complex aortic arch disease.

Products Covered:

• Catheters
• Sheath
• Guide Wires
• Atherectomy Devices
• Embolic Devices
• Stents
• Inferior Vena Cava (IVC)
• Thrombectomy Devices
• Plaque Modification Device
• Hemodynamic Flow Alteration Devices
• Other Products

Procedures Covered:

• Oncology Procedures
• Gastric
• Neurology
• Skin Procedures
• Uteral
• Renal
• Hepatic
• Other Procedures

Applications Covered:

• Venous Thromboembolism
• Peripheral Artery Disease
• Other Applications

End Users Covered:

• Hospitals
• Ambulatory Surgical Centers
• Catheterization Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Peripheral Interventions Market, By Product

• 5.1 Introduction
• 5.2 Catheters
• 5.3 Sheath
• 5.4 Guide Wires
• 5.5 Atherectomy Devices
• 5.6 Embolic Devices
• 5.7 Stents
  • 5.7.1 Bare Metal Stents
  • 5.7.2 Drug-Eluting Stents
• 5.8 Inferior Vena Cava (IVC)
• 5.9 Thrombectomy Devices
• 5.10 Plaque Modification Device
• 5.11 Hemodynamic Flow Alteration Devices
• 5.12 Other Products

6 Global Peripheral Interventions Market, By Procedures

• 6.1 Introduction
• 6.2 Oncology Procedures
• 6.3 Gastric
• 6.4 Neurology
• 6.5 Skin Procedures
• 6.6 Uteral
• 6.6 Renal
• 6.7 Hepatic
• 6.8 Other Procedures

7 Global Peripheral Interventions Market, By Application

• 7.1 Introduction
• 7.2 Venous Thromboembolism
• 7.3 Peripheral Artery Disease
• 7.4 Other Applications

8 Global Peripheral Interventions Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Ambulatory Surgical Centers
• 8.4 Catheterization Laboratories
• 8.5 Other End Users

9 Global Peripheral Interventions Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Boston Scientific Corporation
• 11.2 Abbott Laboratories
• 11.3 W. L. Gore & Associates Inc
• 11.4 AngioDynamics Inc.
• 11.5 Medtronic
• 11.6 Teleflex Incorporated
• 11.6 Cardinal Health Inc
• 11.7 Terumo Corporation
• 11.8 Biotronik SE & Co. KG
• 11.9 C.R. Bard Inc.
• 11.10 Cook Medical
• 11.11 Terumo Interventional Systems Inc
• 11.12 Becton Dickinson and Company
• 11.13 B. Braun Melsungen AG
• 11.14 St. Jude Medical